Jutzi, Jonas S. http://orcid.org/0000-0002-1977-153X
Marneth, Anna E. http://orcid.org/0000-0001-9065-0581
Jiménez-Santos, María José
Hem, Jessica
Guerra-Moreno, Angel
Rolles, Benjamin http://orcid.org/0000-0002-7393-861X
Bhatt, Shruti http://orcid.org/0000-0002-2617-5082
Myers, Samuel A. http://orcid.org/0000-0001-7636-0887
Carr, Steven A.
Hong, Yuning
Pozdnyakova, Olga
van Galen, Peter http://orcid.org/0000-0002-0735-1570
Al-Shahrour, Fátima http://orcid.org/0000-0003-2373-769X
Nam, Anna S.
Mullally, Ann http://orcid.org/0000-0001-9727-8495
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (JU 3104/2-1)
Leukemia and Lymphoma Society (3415-22)
U.S. Department of Defense (W81XWH-20-1-0904)
Deutsche Krebshilfe (70114570)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (U24-CA210986, U01 CA214125)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
Department of Education and Training | Australian Research Council (FT210100271)
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (R01HL131835)
Gabrielle’s Angel Foundation for Cancer Research
Starr Foundation (I15-0026)
Article History
Received: 16 June 2022
Revised: 21 November 2022
Accepted: 25 November 2022
First Online: 6 December 2022
Competing interests
: SAC is a member of the scientific advisory boards of Kymera, PTM BioLabs, Seer and PrognomIQ. AM receives research funding from Relay Therapeutics. AM has consulted for Janssen, PharmaEssentia, Actuate, Constellation, Aclaris Cellarity, Morphic, BioMarin, Protagonist and Incyte. AM has received research funding from Janssen and Actuate Therapeutics.